Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. Kramer BS, Hagerty KL, Justman S, Somerfield MR, Albertsen PC, Blot WJ, Ballentine Carter H, Costantino JP, Epstein JI, Godley PA, Harris RP, Wilt TJ, Wittes J, Zon R, Schellhammer P, American Society of Clinical Oncology Health Services Committee, American Urological Association Practice Guidelines Committee (2009) J Clin Oncol 27: 1502-16 Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial. Fowke JH, Howard L, Andriole GL, Freedland SJ (2014) Eur Urol 66: 1133-8 NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance. Austin DC, Strand DW, Love HL, Franco OE, Grabowska MM, Miller NL, Hameed O, Clark PE, Matusik RJ, Jin RJ, Hayward SW (2016) Prostate 76: 1004-18 Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia. Nichol MB, Knight TK, Wu J, Barron R, Penson DF (2009) J Urol 181: 2214-21; discussion 2221-2
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.